Uricase - Enzon

Drug Profile

Uricase - Enzon

Alternative Names: PEG-uricase - Enzon; Urate oxidase - Enzon

Latest Information Update: 29 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enzon Pharmaceuticals
  • Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gout

Most Recent Events

  • 14 Jan 2014 Biomarkers information updated
  • 26 Aug 1998 No-Development-Reported for Gout in USA (Unknown route)
  • 31 Dec 1994 Phase-I clinical trials for Gout in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top